PEPG · PepGen Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on PEPG. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About PEPG · PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Live Quote
HOLD (score -1) · 12-1 mom 10.8% · RSI 61.9 · above_50_only · -74.6% from high
Targets blend Wall Street consensus (8 analysts: low $3.00 / mean $10.25 / high $20.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
PEPG is a clinical-stage biotech developing PGN-EDODM1 for myotonic dystrophy type 1. The investigation trigger (3 Form 4 filings in 14 days) was satisfied, but all three recent filings are director stock option grants at $1.79 strike — not open-market purchases (P-codes). These are routine compensation events with no directional signal. Separately, a large block of deep-OTM calls on the $1 strike (200 contracts, V/OI=1.08) represents unusual positioning but is at a highly illiquid level with null bid/ask data across most strikes. The stock has collapsed ~76% from its January 2026 high ($7.17) to its March low ($1.32), driven by the catastrophic March 30 Phase II FREEDOM2 data readout — despite management's positive framing, the market interpreted results as disappointing for a lowest-dose cohort. No clear near-term catalyst exists that is both specific and credible enough to reverse this sentiment. The stock trades ~55% below its 200-DMA with thin options liquidity.